PharmaFocus Today – Page 63 – media

Kangleweishi’s nine-valent HPV vaccine research and development has made significant progress

On the evening of February 28, Kangleweishi issued an announcement stating that on the same day, the independent data monitoring committee (IDMC) of the domestic phase III protective efficacy clinical trial of the company’s independently developed recombinant nine-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (Escherichia coli) (female indication) has completed the first analysis unblinding, primary efficacy indicators and safety evaluation, and the company has received the IDMC’s recommendation letter based on the first analysis results. The company stated that the independent data monitoring committee (IDMC) confirmed that the efficacy results met the first analysis statistical criteria preset in the protocol. The first analysis results of the company’s nine-valent HPV vaccine (female indication) domestic phase III protective efficacy clinical trial were in line with expectations, marking a major progress in the clinical research of the nine-valent HPV vaccine. The company said the development is not expected to have a material impact on its ...
- Source: drugdu
- 129
- March 4, 2025
Rabies vaccine market share continues to fall, Chengda Bio’s performance shrinks and it is difficult to break through

Rabies vaccine leader Chengda Bio (688739.SH) recently disclosed its performance report. In 2024, the company achieved operating income of 1.676 billion yuan, a year-on-year decline of 4.22%; and achieved a net profit attributable to the parent of 334 million yuan, a year-on-year decrease of 28.4%. This is the fourth consecutive year that Chengda Bio’s net profit has declined since its listing on the Science and Technology Innovation Board in 2021. Although the company has dominated the domestic human rabies vaccine market for 16 consecutive years since 2008, as more challengers have entered the market, its market share has fallen from more than 70% at its peak to less than 40% in 2024. In recent years, Chengda Bio has tried to find a second growth line, but with little success. The Japanese encephalitis inactivated vaccine launched in 2008 has accounted for less than 10% of the company’s revenue so far, and ...
- Source: drugdu
- 92
- March 4, 2025
Profits soared 8829%! Sinocell’s magnificent comeback

Recently, Sinocell released its 2024 performance report, and the results are quite impressive. In 2024, Sinocell’s total operating revenue was 2.513 billion yuan, a year-on-year increase of 33.13%. Operating profit reached 568 million yuan, a year-on-year increase of 8829.33%, and the net profit attributable to the parent company’s owners was 112 million yuan, successfully turning losses into profits. In addition, the non-net profit also reached 474 million yuan, also turning losses into profits. 1 2 billion single product Sinocell is a leading innovative biopharmaceutical R&D and industrial development company founded by Dr. Xie Liangzhi, an internationally renowned biopharmaceutical expert. The company was listed on the Science and Technology Innovation Board in 2020, and launched its first listed product, recombinant human coagulation factor VIII for injection (Anjiayin) in 2021. In 2024, the company finally turned losses into profits. According to the announcement of Sinocell, the company’s total operating income in 2024 ...
- Source: drugdu
- 138
- March 4, 2025
CanSino Biologics’ 2024 loss narrowed by more than 70%, and the launch of the innovative quadruple vaccine boosted revenue

“Science and Technology Innovation Board Daily” reported on February 28 (special correspondent Gao Qing) that vaccine company CanSino Biologics (688185.SH) released its 2024 performance report. The announcement showed that CanSino Biologics achieved revenue of 846 million yuan in 2024, an increase of 137.01% year-on-year, and a net profit loss of 379 million yuan, a year-on-year reduction of 74.45%. The net profit loss after deducting non-recurring items was 441 million yuan, a year-on-year decrease of 72.61%. Due to a sharp decline in revenue related to the new crown vaccine, CanSino Biologics’ 2023 performance loss once exceeded 1.4 billion yuan. Judging from the latest performance, the company has come out of that low period. In the announcement, CanSino mentioned that the company’s revenue increased significantly compared with the same period last year. The main reason is that its vaccine product Manhaixin®, as the only quadrivalent meningococcal conjugate vaccine in the Chinese market, ...
- Source: drugdu
- 174
- March 3, 2025
The 2025 National Drug Inspection Work Conference was held

The reporter learned from the National Drug Administration that on February 25, the 2025 National Drug Inspection Work Conference was held in Nanchang. The meeting summarized the results of the 2024 drug inspection work, deeply analyzed the current situation, exchanged inspection work experience, and deployed key tasks for 2025. The meeting required that drug regulatory departments and drug testing institutions at all levels strictly implement the “four strictest” requirements, follow the working ideas of “being political, strengthening supervision, ensuring safety, promoting development, and benefiting people’s livelihood”, and jointly carry out drug inspection work, and play an important role in discovering and eliminating risks and hidden dangers, continuously improving drug quality, and ensuring the safety of public drug use. It is necessary to strengthen political guidance, strictly implement responsibilities, firmly establish risk awareness, adhere to problem orientation, strengthen capacity building, improve work mechanisms, coordinate annual drug inspection work, and effectively improve ...
- Source: drugdu
- 170
- March 3, 2025
Two more people under China Pharmaceutical Group were investigated

On February 28, Wang Zhiguang, member of the Party Committee and deputy general manager of China Pharmaceutical and Health Products Co., Ltd. (hereinafter referred to as China Pharmaceutical and Health Products), was suspected of serious violations of discipline and law. He is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of General Technology Group and the Supervision Committee of Xingshan County, Yichang City, Hubei Province; Guo Cui, former manager of the administrative department of Hubei General Pharmaceutical Co., Ltd. (hereinafter referred to as Hubei General), was suspected of serious violations of discipline and law. He is currently undergoing disciplinary review and supervision investigation by the Discipline Inspection and Supervision Group of General Technology Group and the Supervision Committee of Yiting District, Yichang City, Hubei Province. According to Qichacha, China Pharmaceutical and Health Products is a wholly-owned subsidiary of China Pharmaceutical (600056.SH), and China Pharmaceutical ...
- Source: drugdu
- 141
- March 3, 2025
China’s first public REITs fund for pharmaceuticals, China Universal Pharmaceutical REIT, was successfully listed

February 27, China Universal Pharmaceutical REIT (fund code “508084”), the first public REIT for pharmaceutical warehousing and logistics in China, which has attracted much attention from the market, was officially listed on the Shanghai Stock Exchange on February 27, 2025. As the first public REIT in the pharmaceutical industry, the successful issuance of China Universal Pharmaceutical REIT marks a breakthrough in the professional segmentation of project asset categories in my country’s public REITs market, and reflects the innovative practice of the capital market in serving the high-quality development of the real economy. The primary and secondary markets of public REITs continue to be hot China Universal Pharmaceutical REIT, which was completed on February 10, had a subscription multiple of 1,192 times by public investors, setting a new record for public REITs. As a latecomer, Jiuzhoutong Pharmaceutical REIT broke the record of 813.44 times set by the recently listed Guotai Junan ...
- Source: drugdu
- 186
- March 3, 2025
Corning Oncology Pharmaceuticals’ stock price surged after being removed from the Hang Seng Composite Index

At the close of February 27, Corning Oncology Pharmaceuticals-B (09966) closed at HK$6.08, up 22.33%, with a turnover rate of 3.63%, a trading volume of 34.9652 million shares, and a turnover of HK$205 million. The company’s stock price has been “seven consecutive positives”, rising 99.34% since February 3. With the help of AI empowerment, the popularity of innovative drugs has not diminished. The Hong Kong Stock Innovative Drug ETF (159567) rose by 2.86% during the intraday session on February 27, and finally closed at 0.95%, with a turnover of 359 million yuan and a turnover rate of over 73%. Since hitting the bottom on January 13, the Hong Kong Stock Innovative Drug ETF has risen by 30.79%. Hang Seng Index Company recently announced the results of its regular quarterly index adjustments. This coincides with the semi-annual index review of the Hang Seng Composite Index, which will become the main basis ...
- Source: drugdu
- 138
- March 3, 2025
Hong Kong stocks have the highest growth rate in the world! The Hang Seng Index rose in February, close to the full year of 2024. The Hong Kong Stock Exchange made a net profit of 13 billion last year

On February 27, the Hong Kong Stock Exchange (00388.HK) (hereinafter referred to as “HKEX”) disclosed its full-year results for 2024, with full-year revenue and other income of HK$22.4 billion, a year-on-year increase of 9%; profit attributable to shareholders of HK$13 billion, a year-on-year increase of 10%. The Hong Kong Stock Exchange said that although the market conditions continued to fluctuate in 2024, the global economic outlook was relatively optimistic and the market atmosphere improved. This background is beneficial to the trading activities and performance of various markets under the Hong Kong Stock Exchange. In February this year, the Hong Kong stock market performed well, and investors talked about it with great enthusiasm. The Hang Seng Index rose to the top of the world’s major stock market indices. From the beginning of February to February 27, the Hang Seng Index has risen by 17.27%, which is basically the same as the ...
- Source: drugdu
- 161
- March 3, 2025
Children eating bats caused an epidemic. The “strange disease” in the Democratic Republic of the Congo has killed 60 people.

The World Health Organization said that an unexplained epidemic broke out simultaneously in five villages in the Equateur Province in the northwest of the Democratic Republic of the Congo, which has infected 1,100 people and killed 60 people. Most of the dead patients had only about 48 hours from the onset of symptoms to death. Ngashi Ngongo, an official of the Africa Centers for Disease Control and Prevention, said in an online briefing on February 27 that the test report showed that in the Basankusu medical area of Equateur Province, 309 (54.1%) of the 571 patients tested for malaria tested positive. Last year, another mysterious flu-like illness that killed dozens of people in another part of the country was eventually identified as malaria. At the same time, the malaria virus is currently spreading in the Equateur Province. But the WHO said that it has not yet been determined whether there ...
- Source: drugdu
- 142
- March 3, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.